Immupharma PLC Corporate Update - Replacement (1934Y)
May 07 2019 - 3:15AM
UK Regulatory
TIDMIMM
RNS Number : 1934Y
Immupharma PLC
07 May 2019
7 May 2019
ImmuPharma PLC
("ImmuPharma" or the "Company")
CORPORATE UPDATE - replacement
The 'Corporate Update' announcement released on 7 May 2019 at
700am under RNS No 1178Y has been replaced. All material details
remain unchanged. The Notes to Editors have been added. The full
text is shown below.
ImmuPharma PLC (LSE: IMM), the specialist drug discovery and
development company provides an update on ongoing activities.
Lupuzor(TM)
Lupuzor(TM) is the Company's late stage asset for Lupus, a
potential life threatening auto-immune disease. Following the
conclusion of the pivotal Phase III trial in 2018, ImmuPharma
continues to look at opportunities which the Board believes over
the longer term have the potential of bringing Lupuzor(TM) to
market. As part of this strategy, the Company confirms that it
continues to engage with potential corporate partners as well as
consulting with regulatory advisors on potential pathways to
market. Whilst these activities continue the commencement of the
Managed Access Program for Lupuzor(TM) will be postponed until the
Company has further clarification on these activities.
Lupuzor(TM) Extension Study
The Lupuzor(TM) open label extension study, from the original
Phase III trial, with a total of 62 eligible patients recruited
throughout the US and Europe, remains on track to report results in
Q2 2019.
Merger of Elro Pharma and Ureka
ImmuPharma's subsidiaries Elro Pharma Sarl and Ureka Sarl, both
based in France, are focussing on unique technologies: the Nucant
cancer programme (Elro) and the peptide platform (Ureka).
As previously announced, the Company has been exploring its
options to licence, divest or 'spin-off' the technologies of both
of these subsidiaries to unlock their future potential and enhance
value to shareholders.
Following an internal review, the Company's intention is to
merge these two subsidiaries, in order to create a stronger
combined company with a platform technology together with a drug
candidate in clinical development, with a view to securing external
investment either from private equity or through a public listing
on a European stock exchange. This in turn would allow ImmuPharma
PLC to focus on Lupuzor(TM) and the overall P140 platform for
different auto-immune indications. Further details will be
announced in due course.
Incanthera Limited
Further to the announcement of 1 April 2019, all discussions
with Incanthera on the Nucant cancer programme and broader
collaboration discussions have now terminated.
Final Results
ImmuPharma will provide a further update on its operations and
strategy in its Final results for the year ended 31 December 2018,
which are expected to be announced by the end of this month.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014. ("MAR")
For further information please contact:
ImmuPharma PLC (www.immupharma.com) + 44 (0) 207 152 4080
Dimitri Dimitriou, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin +44 (0) 203 368 8974
Vassil Kirtchev
Stanford Capital Partners (Joint Broker)
Patrick Claridge, John Howes +44 (0) 203 815 8880
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
Notes to Editors
About ImmuPharma plc
ImmuPharma (AIM: IMM) is a pharmaceutical development company
listed since 2006 on AIM of the London Stock Exchange focusing on
developing novel medicines with high sales potential in specialist
markets with serious unmet need. ImmuPharma is led by a
commercially focused Board and management team with extensive
experience.
About Lupuzor(TM)
Lupuzor(TM) (also referred to as Forigerimod, or P140) is
ImmuPharma's lead compound and a potential treatment for lupus (or
Systemic Lupus Erythematosus), a chronic, potentially
life-threatening auto-immune disease. Lupuzor(TM) has a novel
mechanism of action aimed at modulating the body's immune system so
that it does not attack healthy cells, and avoids causing adverse
side effects. It has the potential to halt the progression of the
disease in a substantial proportion of patients.
The completed pivotal Phase III clinical trial was entitled "A
52-Week, Randomized, Double-Blind, Parallel-Group,
Placebo-Controlled Study to Evaluate the Efficacy and Safety of a
200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With
Systemic Lupus Erythematosus". Top line data was announced on 17
March 2018. The data showed that Lupuzor(TM) demonstrated a
superior response rate over placebo (52.5% vs 44.6% "responders")
in the primary analysis on the Full Analysis Set of all 202
patients. Importantly the study confirmed the outstanding safety
profile of Lupuzor(TM), with no serious adverse events being
reported. However, due to the high response rate in the placebo
group, this superior response did not allow statistical
significance to be reached (p = 0.2631) and the trial's primary end
point was not met. For more information go to:
http://www.immupharma.co.uk/top-line-results-lupuzor-pivotal-phase-iii-trial.
P140 Platform
ImmuPharma together with Professor Sylviane Muller, Lupuzor's
inventor, have presented evidence supporting Lupuzor's(TM)
Forigerimod / P140 peptide activity in several other major
auto-immune disease indications outside of Lupus including
Rheumatoid Arthritis, Crohn's Disease, and Asthma. In particular,
the peptide appears to have general effects against chronic
inflammatory indications. Other pre-clinical evidence supports the
molecule's use in: Neuropsychiatric lupus (NPSLE); Gougerot-Sjögren
syndrome (GSS); and Guillain-Barre disease (chronic/CIDP).
For more information, please visit www.immupharma.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
UPDDDLBBKEFFBBF
(END) Dow Jones Newswires
May 07, 2019 03:15 ET (07:15 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024